Evidence map›Paper›PMID 34209150›Full record

ArticleNutrients2021

Up-Regulation of Specific Bioactive Lipids in Celiac Disease.

Rafael Martín-Masot, Jose Daniel Galo-Licona, Natàlia Mota-Martorell, Joaquim Sol, Mariona Jové, José Maldonado, Reinald Pamplona, Teresa Nestares

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Rafael Martín-MasotPediatric Gastroenterology and Nutrition Unit, Hospital Regional Universitario de Malaga, 29011 Málaga, Spain.ORCID 0000-0003-0113-9904
Jose Daniel Galo-LiconaDepartment of Experimental Medicine, Lleida Biomedical Research Institute (IRBLleida), University of Lleida (UdL), 25198 Lleida, Spain.
Natàlia Mota-MartorellDepartment of Experimental Medicine, Lleida Biomedical Research Institute (IRBLleida), University of Lleida (UdL), 25198 Lleida, Spain.ORCID 0000-0001-5937-7070
Joaquim SolDepartment of Experimental Medicine, Lleida Biomedical Research Institute (IRBLleida), University of Lleida (UdL), 25198 Lleida, Spain.ORCID 0000-0003-1424-8958
Mariona JovéDepartment of Experimental Medicine, Lleida Biomedical Research Institute (IRBLleida), University of Lleida (UdL), 25198 Lleida, Spain.
José MaldonadoDepartment of Pediatrics, University of Granada, 18071 Granada, Spain.
Reinald PamplonaDepartment of Experimental Medicine, Lleida Biomedical Research Institute (IRBLleida), University of Lleida (UdL), 25198 Lleida, Spain.ORCID 0000-0003-4337-6107
Teresa NestaresBiomedical Research Centre (CIBM), Department of Physiology and "José MataixVerdú", Institute of Nutrition and Food Technology (INYTA), University of Granada, 18071 Granada, Spain.ORCID 0000-0002-9573-3244
Universitat de Lleida · ESUniversidad de Granada · ESHospital Regional Universitario de Málaga · ES

Funding

Department of Health SLT002/16/00250Generalitat of Catalonia: Agency for Management of University and Research Grants 2017SGR696Regional Government of Andalusia, Excellence Research Project P12-AGR-2581Spanish Ministry of Science, Innovation, and Universities RTI2018-099200-BI00
6 · The paper itself

Abstract

Celiac disease (CD) is an autoimmune enteropathy linked to alterations of metabolism. Currently, limited untargeted metabolomic studies evaluating differences in the plasma metabolome of CD subjects have been documented. We engage in a metabolomic study that analyzes plasma metabolome in 17 children with CD treated with a gluten-free diet and 17 healthy control siblings in order to recognize potential changes in metabolic networks. Our data demonstrates the persistence of metabolic defects in CD subjects in spite of the dietary treatment, affecting a minor but significant fraction (around 4%, 209 out of 4893 molecular features) of the analyzed plasma metabolome. The affected molecular species are mainly, but not exclusively, lipid species with a particular affectation of steroids and derivatives (indicating an adrenal gland affectation), glycerophospholipids (to highlight phosphatidic acid), glycerolipids (with a special affectation of diacylglycerols), and fatty acyls (eicosanoids). Our findings are suggestive of an activation of the diacylglycerol-phosphatidic acid signaling pathway in CD that may potentially have detrimental effects via activation of several targets including protein kinases such as mTOR, which could be the basis of the morbidity and mortality connected with untreated CD. However, more studies are necessary to validate this idea regarding CD.

Indexed as

Up-RegulationAdolescentCeliac DiseaseChildChild, PreschoolFemaleHumansLipid MetabolismLipidsMaleMetabolomeMetabolomicsLipidsceliac diseasediacylglycerolsfatty acylsglycerophospholipidsmass spectrometryplasma metabolomicssteroids

Identifiers

PMID34209150
PMCPMC8308317
OpenAlexW3174352281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.